StockData

Amarin vs Kamada

AMRN and KMDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMRN and KMDA compare

Kamada grew revenue faster over the last twelve months (13.2% versus −22.3% for Amarin).

Amarin scores higher on the StockData Score (10 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMRNKMDA
Size and price
Market cap$5.0B–
Share price$11.38$8.09
Change, 1 year−29.8%11.1%
Change, 5 years−85.4%44.5%
Beta (5Y)1.540.76
Employees80393
StockData Score
Total score10 (better)5
Valuation score00
Growth score12 (better)
Performance score3 (better)0
Health score6 (better)3
Dividend score00
Valuation
P/S28.6×–
P/B11.3×–
Fair value$7.00–
Margin of safety−62.5%–
Growth
Revenue growth (TTM)−22.3%13.2% (better)
Revenue growth, 5Y average−19.0%6.3% (better)
EPS growth, 5Y average–−1.6%
Profitability
Gross margin40.9% (better)40.8%
Operating margin−18.2%14.5% (better)
Net margin−10.9%–
Return on equity−4.2%–
Return on invested capital−17.3%–
Financial health
Debt / equity0.00–
Net debt / EBITDA–−0.54
Interest coverage–26.8×
Current ratio3.504.06 (better)
Altman Z-score13.05–
Piotroski F-score7–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions1.0%8.6%
Held by insiders7.0%45.3%
Insider net buying, 12 months–−$1.7M
Short interest, % of float–0.53%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.